GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Global Blood Therapeutics Inc (NAS:GBT) » Definitions » Price-to-Tangible-Book

Global Blood Therapeutics (Global Blood Therapeutics) Price-to-Tangible-Book : 38.94 (As of May. 25, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Global Blood Therapeutics Price-to-Tangible-Book?

As of today (2024-05-25), Global Blood Therapeutics's share price is $68.49. Global Blood Therapeutics's Tangible Book per Share of Jun. 2022 for the quarter that ended in Jun. 2022 was $1.76. Hence, Global Blood Therapeutics's Price to Tangible Book Ratio of today is 38.94.

The historical rank and industry rank for Global Blood Therapeutics's Price-to-Tangible-Book or its related term are showing as below:

GBT' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.69   Med: 5.34   Max: 38.91
Current: 38.91

During the past 9 years, Global Blood Therapeutics's highest Price to Tangible Book Ratio was 38.91. The lowest was 2.69. And the median was 5.34.

GBT's Price-to-Tangible-Book is not ranked
in the Biotechnology industry.
Industry Median: 2.79 vs GBT: 38.91

A closely related ratio is called PB Ratio. As of today, Global Blood Therapeutics's share price is $68.49. Global Blood Therapeutics's Book Value per Sharefor the quarter that ended in Jun. 2022 was $1.76. Hence, Global Blood Therapeutics's P/B Ratio of today is 38.94.


Global Blood Therapeutics Price-to-Tangible-Book Historical Data

The historical data trend for Global Blood Therapeutics's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Global Blood Therapeutics Price-to-Tangible-Book Chart

Global Blood Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Price-to-Tangible-Book
Get a 7-Day Free Trial Premium Member Only 5.69 3.99 8.33 6.44 9.63

Global Blood Therapeutics Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.92 5.32 9.63 16.82 18.16

Competitive Comparison of Global Blood Therapeutics's Price-to-Tangible-Book

For the Biotechnology subindustry, Global Blood Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Global Blood Therapeutics's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Global Blood Therapeutics's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Global Blood Therapeutics's Price-to-Tangible-Book falls into.



Global Blood Therapeutics Price-to-Tangible-Book Calculation

Global Blood Therapeutics's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Jun. 2022 )
=68.49/1.759
=38.94

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Global Blood Therapeutics Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Global Blood Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Global Blood Therapeutics (Global Blood Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
181 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Global Blood Therapeutics Inc operates in the healthcare sector of the United States. It discovers and develops novel therapeutics to address blood-based disorders. GBT440, its lead drug candidate targets the underlying mechanism of red blood cell (RBC) sickling, which provides the potential to treat sickle cell disease. GBT440. an oral, once-daily therapy arrests abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. In addition, the company is engaged in other research and development activities targeted at hereditary angioedema and owns exclusively licensed rights to its portfolio of product candidates in the United States, Europe, and other major markets.
Executives
Jeffrey S Farrow officer: Chief Financial Officer TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Nazila Habibizad officer: See Remarks C/O GLOBAL BLOOD THERAPEUTICS, INC. 181 OYSTER POINT BLVD SOUTH SAN FRANCISCO CA 94080
Dawn Svoronos director C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Philip A. Pizzo director ONE COMMERCE STREET, SUITE 2550, MEMPHIS TN 38103
Scott W Morrison director C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT SUITE 101, SOUTH SAN FRANCISCO CA 94080
Carrie Krehlik officer: Chief Human Resources Officer 6015 COLTON BLVD, OAKLAND CA 94611
Eric Fink officer: Chief Human Resources Officer C/O GLOBAL BLOOD THERAPEUTICS, INC. 171 OYSTER POINT BLVD., SUITE 300 SOUTH SAN FRANCISCO CA 94080
Kim Smith-whitley officer: See Remarks C/O GLOBAL BLOOD THERAPEUTICS, INC. 181 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Alexis A. Thompson director C/O GLOBAL BLOOD THERAPEUTICS, INC. 181 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Brian Edwin Cathers officer: Chief Scientific Officer C/O GLOBAL BLOOD THERAPEUTICS, INC. 171 OYSTER POINT BLVD., SUITE 300 SOUTH SAN FRANCISCO CA 94080
Lesley Ann Calhoun officer: See Remarks C/O GLOBAL BLOOD THERAPEUTICS, INC., 171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Mark L Perry director 176 WEST BLITHEDALE AVE, MILL VALLEY CA 94941
Ted W Love director, officer: See Remarks C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080
Tricia Borga Suvari officer: Chief Legal Officer 3172 PORTER DRIVE PALO ALTO CA 94034
Brown Willie L. Jr. director C/O GLOBAL BLOOD THERAPEUTICS, INC. 400 EAST JAMIE COURT, SUITE 101 SOUTH SAN FRANCISCO CA 94080

Global Blood Therapeutics (Global Blood Therapeutics) Headlines

From GuruFocus

Top 5 4th Quarter Trades of BAKER BROS. ADVISORS LP

By GuruFocus Research GuruFocus Editor 02-18-2023

GBT Announces New Employment Inducement Grants

By PurpleRose PurpleRose 07-15-2022